Form 4: Cytokinetics Director Acquires Shares in Lieu of Cash Retainer

Director Robert Arthur Harrington acquired 237 shares of Cytokinetics Inc. common stock on October 1, 2024, in lieu of a cash retainer payment.

Summary

• Robert Arthur Harrington, a director of Cytokinetics Inc., acquired 237 shares of common stock on October 1, 2024.
• The acquisition was made in lieu of a cash retainer payment.
• The price per share was $52.6.
• Following the transaction, Harrington beneficially owns 15,753 shares of Cytokinetics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (director receiving stock instead of cash). It doesn't inherently indicate positive or negative sentiment, but the director's willingness to take stock could be seen as a mild positive.

Positives

• Director's acquisition of shares may signal confidence in the company's future prospects.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, particularly for smaller companies or those looking to conserve cash. It aligns the director's interests with those of shareholders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It may slightly increase shareholder confidence due to the director's increased stake in the company.

Key Dates